Fri, Jan 30, 2015, 12:12 AM EST - U.S. Markets open in 9 hrs 18 mins

Recent

% | $
Quotes you view appear here for quick access.

Antares Pharma Inc. Message Board

paras_hemrajani 7 posts  |  Last Activity: Jan 26, 2015 11:48 AM Member since: Dec 19, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Sumatripan complete response letter

    by nammuang Jan 26, 2015 7:09 AM
    paras_hemrajani paras_hemrajani Jan 26, 2015 11:48 AM Flag

    Hoping not expecting Nam, as i stated they miss every realistic expectation, so you can only pray or hope at this point.

    When i bought in 2012-3, i had also hoped Otrexup would have $50+ million in sales in 2015, with Epipen's approval company sales at $100 million and a stock price around $8 in 2015. Not happening. Never thought this would be such a disaster.

  • paras_hemrajani paras_hemrajani Jan 26, 2015 9:23 AM Flag

    Hoping for more than Gelnique :-). During the JP Morgan conference James F stated that Teva lost interest in the program, but we still tried to pursue them to keep it going. They will not care about selling the product. But our mgmt is happy to boast about the 50-50 split in revenues.

  • Reply to

    Sumatripan complete response letter

    by nammuang Jan 26, 2015 7:09 AM
    paras_hemrajani paras_hemrajani Jan 26, 2015 9:18 AM Flag

    Simple answer, not a very active investor, only got time to research and invest in 5 companies at this time. I am also down a good bit i.e. 25% on my investment and I am not sure why i still think this company gives me the best shot of recovering my loss in the next 6 months. Trust me, I am happy to move on after going thru the following events in the past year:
    -Find out about competition for Otrexup
    -Otrexup Lawsuit
    -Paul Wotton's resignation/firing
    -Otrexup's disappointing sales/Sales Force Issues
    -Firing of Leroux
    -Tev Tropin recall
    -Likely delay in QST Program
    -Today's CRL

    I am having difficulty recalling any good news, oh maybe Rasuvo did not have a great launch and the company was able to dupe LEO into giving us $10 million and potentially another $10 million, but that's not going to happen if Otrexup sales for LEO are less than $1 million dollars for last year.

    We are all just hoping for an AB rated Epipen, else we are toast and are going to see a much lower share price.

  • Reply to

    Sumatripan complete response letter

    by nammuang Jan 26, 2015 7:09 AM
    paras_hemrajani paras_hemrajani Jan 26, 2015 8:37 AM Flag

    It amazes me how this company continues to fail in every program they work on and are never able to meet realistic investor expectations. I can't understand why it takes 10+ years to have this drug on the market. Hobbs statement in the press release today pretty much proves that he is a loser. I can't wait to breakeven and sell my stock. Simply sick and tired of living thru all these failures with this company.

  • Reply to

    Epi-pen potential

    by cacheflash57 Dec 10, 2014 4:36 PM
    paras_hemrajani paras_hemrajani Dec 10, 2014 8:15 PM Flag

    You also missed that not all sales translates into net profit. Device sales has a COGS component to it, only royalties translate to profit. I think Larry's estimate that Epipen will contribute 20 cents net profit in 2016 is a good target for the company. They obviously will find a way to miss it and give a good excuse, but that does not stop speculators from makeing a case that Epipen's contributions to ATRS should be $3/share (P/E = 15), hence the stock price should be $5+/share if the Instapen is AB rated.

  • Reply to

    current thoughts on ATRS

    by tappyt_2014 Nov 17, 2014 11:07 AM
    paras_hemrajani paras_hemrajani Nov 18, 2014 6:16 AM Flag

    Tappy,
    I am a long investor and started investing in this company in early 2012.
    Below are a few points i would like to debate:
    1. You state - Jack Howarth is easily reachable by all shareholders and for anyone concerned with corporate communications - He is there to give explain any confusion or misconception about ATRS.

    My response: JH is an incompetent employee at Antares Pharma and should consider himself lucky to be on the payroll. He adds no value and often misleads investors. His investment in this company is underwater and he is one of the few insiders i have followed that have accumulated a large position (relative to their net worth) in the stock only to see it go down significantly. Talking to him is a complete waste of time as he will only provide you with incorrect or useless facts. Take note Bob Apple - Save us some G&A expenses.

    2. You state - The best risk / reward opportunity I have seen in the market in a very long time

    My response - If your universe of stocks is limited to one company, then i guess your statement makes sense. ATRS has significantly underperformed the majority of the stocks in the market for the last 1,2 and 3 years and this will not change until a buyout.

    The company has failed with the Otrexup launch as i doubt they will have more than $20 million in 2015 net sales. Its only saving grace is Teva purchasing it for $4 in 2015.

    Paul + Leroux + JH = Scammers!

    Anyone interested to do a dark pool trade at $3.06 and relieve me of my shares. Please get me out of here :-) !!!

  • Reply to

    October versus July plus 45%

    by nammuang Nov 7, 2014 6:09 AM
    paras_hemrajani paras_hemrajani Nov 7, 2014 6:26 AM Flag

    The bad news is Oct vs September is flat.
    For 2014 Net sales for Otrexup will be around $8 million
    For 2015, we will be lucky to see $20 million in new sales for Otrexup

    It is not a good sign when the first item the company discusses on its earnings call is QST, which is over 2 years away from producing any revenue for the company.

    Otrexup launch has been a failure and shame on Wotton & Leroux for lying on peak sales.

    I am long because of Epipen, but will be eager to get rid of this stock from my portfolio hopefully sometime next year.

ATRS
2.38+0.11(+4.85%)Jan 29 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Core Laboratories NV
NYSEThu, Jan 29, 2015 4:00 PM EST
QUALCOMM Incorporated
NASDAQThu, Jan 29, 2015 4:00 PM EST